

ANNOUNCING

Canada's Premiere Virtual Cardiovascular Symposium

CardioMet'24 will be Canada's premiere, virtual cardiovascular symposium. Aimed at cardiovascular specialists, this multi-day virtual conference will highlight topics of major interest or controversy across six therapeutic themes. Featuring world-class faculty, interactivity, and cutting edge science, CardioMet'24 will be unlike any other cardiovascular conference in Canada.

19th & 26th JANUARY 2024

12:00 – 6:00 pm EST

Program Themes

19th JANUARY 2024

- Imaging
- Structural Heart
- CAD/ACS

26th JANUARY 2024

- Atrial Fibrillation
- Heart Failure
- Prevention

Register Now!

This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by the McMaster University Continuing Professional Development Program. You may claim a maximum of 10 MOC Section 1 hours (credits are automatically calculated).

CardioMet^{'24}
Canada's Premiere Virtual Cardiovascular Symposium

Opening Address



Robert M. Califf

MD
Commissioner,
Food and Drug Administration

Keynote Speakers



Ami Bhatt

MD, FACC
Chief Innovation Officer,
American College of Cardiology



Eugene Braunwald

MD, MACC
Harvard University

Learning Objectives:

- ✓ Discuss the latest advances in cardiovascular risk factor management and prevention.
- ✓ Explain new developments in the management of heart failure and atrial fibrillation.
- ✓ Explore new imaging techniques employed in the management of structural heart disease.

Registration

Visit: www.ccrnmd.com

For inquiries regarding this program, please contact info@ccrnm.com.



This program has received an educational grant from:

Innovation Level – HLS Therapeutics

Impact Level – Amgen, Novartis

Benefactor Level – Anthos Therapeutics, AstraZeneca

AGENDA

Friday, January 19th, 2024



CardioMet²⁴
Canada's Premiere Virtual Cardiovascular Symposium



Milan Gupta

12:00 - 12:10

Welcome and opening remarks

OPENING ADDRESS

12:10 - 12:30

ROLE OF FDA IN COMBATTING THE PUBLIC HEALTH THREAT OF CARDIOMETABOLIC DISEASE **Robert M. Califf**

12:30 - 12:40

DISCUSSION

KEYNOTE ADDRESS

12:40 - 1:00

AI AND CARDIOLOGY: FRIEND OR FOE?

Ami Bhatt

1:00 - 1:10

DISCUSSION

IMAGING

Moderators: Margot Davis/Jacob Udell

1:15 - 1:35

ASSESSMENT OF CORONARY PLAQUE IN THE CATH LAB: BEYOND ANGIOGRAPHY **Erick Schampaert**

1:35 - 1:55

CARDIAC CT ANGIOGRAPHY: STRENGTHS AND LIMITATIONS

Jonathan Leipsic

1:55 - 2:15

PRACTICAL APPLICATIONS OF CARDIAC MRI

Kate Hanneman

2:15 - 2:35

DISCUSSION

Learning Objectives

- Describe the role of the FDA in helping to manage cardiometabolic disease
- Identify the current and future role of AI in cardiology
- Evaluate new and emerging strategies for coronary plaque assessment
- Describe the role and value of Cardiac CT angiography and cardiac MRI as a diagnostic tool

2:35 - 2:55

REFRESHMENT BREAK

STRUCTURAL HEART

Moderators: Margot Davis/Anique Ducharme

3:00 - 3:20

CHALLENGES IN TAVR: BICUSPID VALVES AND ASYMPTOMATIC PATIENTS

David Wood

3:20 - 3:40

MITRAL TEER: SELECTING THE RIGHT PATIENT

Anique Ducharme

3:40 - 4:00

TRICUSPID REGURGITATION: INNOCENT BYSTANDER OR CULPRIT?

Louis-Philippe David

4:00 - 4:20

DISCUSSION

Learning Objectives

- Explore the growing role of TAVR in bicuspid valves and asymptomatic patients
- Identify patients who can most benefit from Mitral TEER procedure
- Determine the association between tricuspid regurgitation and long-term outcomes

CAD/ACS

Moderators: Milan Gupta/Jacob Udell

4:25 - 4:45

CULPRIT LESION OR COMPLETE REVASCULARIZATION FOR ACS?

Shamir Mehta

4:45 - 5:05

DAPT FOLLOWING ACS: DOES ONE SIZE FIT ALL?

Marc Bonaca

5:05 - 5:25

DOES PCI FOR STABLE CAD OFFER ANY BENEFITS?

Rasha Al-Lamee

5:25 - 5:45

SHOULD COLCHICINE BECOME STANDARD THERAPY FOR CAD?

Paul Ridker

5:45 - 6:10

DISCUSSION

Learning Objectives

- Distinguish the appropriate revascularization strategy for ACS patients
- Describe the evolving role of DAPT following ACS
- Review the clinical benefits of PCI in stable angina
- Identify the role of colchicine and vascular inflammation as a target of therapy

6:10 - 6:15

MEETING CLOSE

Milan Gupta

12:00 - 12:25 **Unaccredited Session**

12:25 - 12:35 Welcome and opening remarks

Milan Gupta

ATRIAL FIBRILLATION Moderators: Milan Gupta/Jacob Udell

12:40 - 12:55 ABLATION - WHO, WHEN AND HOW?

Jason Andrade

12:55 - 1:10 LEFT ATRIAL APPENDAGE CLOSURE - WHO, WHEN AND HOW?

Jacqueline Saw

1:10 - 1:25 ARE FACTOR XI/XIa INHIBITORS THE FUTURE OF STROKE PREVENTION?

Christian Ruff

1:25 - 1:40 WEARABLES AND AF DETECTION: HOW MUCH IS ENOUGH?

Chris Cheung

1:40 - 2:00 DISCUSSION

Learning Objectives

- Determine the ideal patient and ablation type for AF
- Examine the role of LAAC for stroke prevention
- Explore the emerging role of Factor XI/XIa Inhibitors in stroke prevention
- Determine the minimum duration of AF required for stroke prevention strategies

KEYNOTE ADDRESS

2:05 - 2:30 HYPERTROPHIC CARDIOMYOPATHY: THE PAST, THE PRESENT, AND THE FUTURE

Eugene Braunwald

2:30 - 2:40 DISCUSSION

2:40 - 3:05 REFRESHMENT BREAK
HEART FAILURE Moderators: Margot Davis/Milan Gupta

3:10 - 3:25 HFpEF, HFmrEF, HFrEF: ONE DISEASE OR NOT?

Biykem Bozkurt

3:25 - 3:40 OPTIMIZING TREATMENT QUICKLY IN HFrEF: A PRACTICAL APPROACH

Peter Liu

3:40 - 3:55 DIAGNOSIS AND TREATMENT OF CARDIAC AMYLOIDOSIS

Margot Davis

3:55 - 4:10 DISCUSSION

Learning Objectives

- Apply new treatment options in patients with hypertrophic cardiomyopathy
- Examine the similarities and differences between HFpEF, HFmrEF, HFrEF
- Apply best practices to rapidly optimize treatment for HFrEF patients
- Explain guideline centric diagnostic and new treatment strategies for Cardiac Amyloidosis

PREVENTION Moderators: Milan Gupta/Jacob Udell

4:15 - 4:35 THE DISRUPTIVE SCIENCE OF LDL-LOWERING: FROM STATINS TO PCSK9 MANIPULATION

Milan Gupta

4:35 - 4:55 DECODING THE CARDIOVASCULAR BENEFITS OF ICOSAPENT ETHYL

Deepak L. Bhatt

4:55 - 5:15 IS Lp(a) THE NEXT FRONTIER?

Marlys Koschinsky

5:15 - 5:35 IS OBESITY MANAGEMENT THE NEXT FRONTIER?

A. Michael Lincoff

5:35 - 6:00 DISCUSSION

Learning Objectives

- Summarize the revolution and future developments in the arena of LDL-Lowering
- Examine the role of triglycerides and icosapent ethyl in cardiovascular risk reduction
- Explore the potential of Lp(a) lowering for CV risk reduction
- Explain the advances in obesity management and future opportunities for risk reduction

6:00 - 6:05 **CLOSING COMMENTS**

Milan Gupta

